Chargement en cours...
Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance
Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system. With its overall dismal prognosis (the median survival is 14 months), GBMs demonstrate a resounding resilience against all current treatment modalities. The absence of a major progress in the treatment of GB...
Enregistré dans:
| Publié dans: | Int J Mol Sci |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6032212/ https://ncbi.nlm.nih.gov/pubmed/29899215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19061765 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|